Glenmark Pharma: Ashish Dhawan portfolio stock surges 9% as USFDA clears Aurangabad unit

September 23, 2024
Uncategorized

Brokerage firm Investec expects that earnings momentum, along with strong cash flow generation, will continue to support the company’s ongoing re-rating.

Glenmark Pharma: Ashish Dhawan portfolio stock surges 9% as USFDA clears Aurangabad unit

Leave a ReplyCancel Reply

Shiprocket files confidential DRHP with SEBI to raise nearly ₹2,500 crore in IPO: Sources

GMM Pfaudler posts ₹27-crore Q4 loss before one-time costs; declares dividend

Mankind Pharma Q4 Results: Profit drops, revenue surges 27% on-year

TeamLease Q4 profit rises 35% on improved operating efficiency, margins improve

Hindustan Zinc wins bid for 308.3-hectare tungsten block in Andhra Pradesh